About Nuvation Bio Inc
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.nuvationbio.com/
Frequently Asked Questions
What is the 52-week range for NUVB?
The 52-week high is $9.75 and the 52-week low is $3.36.
What is the P/E ratio for NUVB?
The P/E ratio data is currently unavailable.
What is the dividend yield for NUVB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -49.73%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -88.19%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 10.08.
Analyst Recommendation Trends
Wall Street analyst consensus for NUVB over the last few months:
Latest NUVB News
Top Penny Stocks To Own In October 2026
Spiking Treasury yields have pushed many investors back toward safer assets, which has punished weaker balance sheets and rewarded stronger ones. That creates an opening for you. Solid, low priced companies that already showed gains over the past year and still look cheap on fundamental metrics suddenly look more interesting. This article examines three such penny stocks that combine financial resilience with positive analyst growth forecasts. The three elite penny stocks in this article are...
This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Sector Update: Healthcare Stocks Rise Thursday Afternoon
Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.5% and the State
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes to the safety sections of labeling with longer follow-up and no new safety signals identifiedApproval comes four months
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups
Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemotherapy exposure. IBTROZI efficacy was reported as consistent across different ROS1 fusion partners in patients with advanced ROS1+ non small cell lung cancer. These IBTROZI subgroup findings matter, but investors may wish to weigh them alongside...
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target
Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Nuvation Bio Inc. (NUVB) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 1:35 PM EDTCompany ParticipantsDavid Hung - Founder,...
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating IBTROZI® (taletrectinib) in both TKI- naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The data, presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea, demonstrated that IBTROZ
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroupsAmong
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Nuvation Bio Inc. (NUVB) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 9:20 AM EDTCompany ParticipantsDavid Hung - Founder, President,...
Jim Cramer sends strong 5-word message on surging biotech stock
Cramer flagged the company as too risky for most people, even as the stock climbs on real medical news.
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary | -100,000 | - | - |
| 2026-08-19 | Hattersley Gary | -100,000 | $7.0924 | $709,240 |
| 2026-08-19 | Hattersley Gary | +100,000 | $1.87 | $187,000 |
| 2026-07-15 | Sauvage Philippe | -1 | - | - |
| 2026-07-15 | Sauvage Philippe | -39,999 | - | - |
| 2026-07-15 | Sauvage Philippe | +1 | $1.97 | $2 |
| 2026-07-15 | Sauvage Philippe | +39,999 | $2.17 | $86,798 |
| 2026-06-23 | Sauvage Philippe | -47,668 | - | - |
| 2026-06-23 | Sauvage Philippe | -47,668 | $6.0076 | $286,370 |
| 2026-06-23 | Sauvage Philippe | +47,668 | $2.17 | $103,440 |
| 2026-06-23 | Markel Stacy | -34,620 | - | - |
| 2026-06-23 | Markel Stacy | -90,380 | - | - |
| 2026-06-23 | Markel Stacy | -125,000 | $6.0255 | $753,188 |
| 2026-06-23 | Markel Stacy | +34,620 | $1.74 | $60,239 |
| 2026-06-23 | Markel Stacy | +90,380 | $1.87 | $169,011 |
| 2026-06-23 | Wentworth Kerry | -63,000 | - | - |
| 2026-06-23 | Wentworth Kerry | -63,000 | $6.0189 | $379,191 |
| 2026-06-23 | Wentworth Kerry | +63,000 | $2.93 | $184,590 |
| 2026-06-09 | Mashal Robert | +25,000 | $4.73 | $118,250 |
| 2026-05-21 | Mashal Robert | +123,397 | - | - |
| 2026-05-21 | Bazemore Robert B | +123,397 | - | - |
| 2026-05-21 | Cui Xiangmin | +123,397 | - | - |
| 2026-05-21 | VERNON W ANTHONY | +123,397 | - | - |
| 2026-05-21 | BLICKENSTAFF KIM D | +123,397 | - | - |
| 2026-05-21 | FALBERG KATHRYN E | +123,397 | - | - |
| 2026-04-17 | Liu Dongfang | -50,000 | - | - |
| 2026-04-17 | Liu Dongfang | -50,000 | $5.02 | $251,000 |
| 2026-04-17 | Liu Dongfang | +50,000 | $1.94 | $97,000 |
| 2026-04-17 | Wentworth Kerry | -36,750 | - | - |
| 2026-04-17 | Wentworth Kerry | -36,750 | $5.0144 | $184,279 |
| 2026-04-17 | Wentworth Kerry | +36,750 | $2.93 | $107,678 |
| 2026-04-06 | Wentworth Kerry | -100,000 | - | - |
| 2026-04-06 | Wentworth Kerry | -100,000 | - | - |
| 2026-04-06 | Wentworth Kerry | -200,000 | $4.5178 | $903,560 |
| 2026-04-06 | Wentworth Kerry | +100,000 | $1.94 | $194,000 |
| 2026-04-06 | Wentworth Kerry | +100,000 | $1.87 | $187,000 |
| 2026-02-27 | Cui Xiangmin | +76,923 | - | - |
| 2026-02-27 | Sauvage Philippe | +748,130 | - | - |
| 2026-02-27 | Sjogren Colleen | +748,130 | - | - |
| 2026-02-27 | Makunje Moses | +224,439 | - | - |
| 2026-02-27 | Makunje Moses | +50,761 | - | - |
| 2026-02-27 | Liu Dongfang | +748,130 | - | - |
| 2026-02-27 | Hanley David C. | +748,130 | - | - |
| 2026-02-27 | Markel Stacy | +748,130 | - | - |
| 2026-02-27 | Hattersley Gary | +748,130 | - | - |
| 2026-02-27 | Cui Xiangmin | +74,813 | - | - |
| 2026-02-27 | Wentworth Kerry | +748,130 | - | - |
| 2026-02-27 | Hung David | +1,995,012 | - | - |
| 2025-12-01 | Liu Dongfang | -150,000 | - | - |
| 2025-12-01 | Liu Dongfang | -150,000 | $7.8217 | $1,173,255 |
| 2025-12-01 | Liu Dongfang | +150,000 | $2.93 | $439,500 |
| 2025-11-26 | Liu Dongfang | -10,000 | - | - |
| 2025-11-26 | Liu Dongfang | -10,000 | $8 | $80,000 |
| 2025-11-26 | Liu Dongfang | +10,000 | $3.61 | $36,100 |
| 2025-11-25 | Liu Dongfang | -10,000 | - | - |
| 2025-11-25 | Liu Dongfang | -10,000 | $7.5 | $75,000 |
| 2025-11-25 | Liu Dongfang | +10,000 | $3.61 | $36,100 |
| 2025-11-20 | Liu Dongfang | -20,000 | - | - |
| 2025-11-20 | Liu Dongfang | -20,000 | $7.0037 | $140,074 |
| 2025-11-20 | Liu Dongfang | +20,000 | $1.87 | $37,400 |
| 2025-11-20 | Hattersley Gary | -300,000 | - | - |
| 2025-11-20 | Hattersley Gary | -69,051 | - | - |
| 2025-11-20 | Hattersley Gary | -300,000 | $7.227 | $2,168,100 |
| 2025-11-20 | Hattersley Gary | +300,000 | $1.94 | $582,000 |
| 2025-11-20 | Hattersley Gary | -69,051 | $7.227 | $499,032 |
| 2025-11-20 | Hattersley Gary | +69,051 | $1.74 | $120,149 |
| 2025-11-19 | Hanley David C. | -200,000 | - | - |
| 2025-11-19 | Hanley David C. | -200,000 | $7.1384 | $1,427,680 |
| 2025-11-19 | Hanley David C. | +200,000 | $1.87 | $374,000 |
| 2025-11-19 | Liu Dongfang | -15,000 | - | - |
| 2025-11-19 | Liu Dongfang | -15,000 | $5.1035 | $76,553 |
| 2025-11-19 | Liu Dongfang | +15,000 | $1.87 | $28,050 |
| 2025-11-17 | Liu Dongfang | -15,000 | - | - |
| 2025-11-17 | Liu Dongfang | -15,000 | $4.765 | $71,475 |
| 2025-11-17 | Liu Dongfang | +15,000 | $1.87 | $28,050 |
| 2025-10-27 | Hattersley Gary | -100,000 | - | - |
| 2025-10-27 | Hattersley Gary | -100,000 | $5.0246 | $502,460 |
| 2025-10-27 | Hattersley Gary | +100,000 | $1.74 | $174,000 |